+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

GC Biopharma Corp (006280) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 57 Pages
  • September 2026
  • GlobalData
  • ID: 5622543
GC Biopharma Corp (006280) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GC Biopharma Corp (GC Biopharma), formerly GC Pharma, provides plasma protein therapeutics and vaccines. The company develops, manufactures, and markets plasma-derived products, including albumin, immunoglobulin, and antithrombin. It also produces vaccines to prevent infectious diseases and a portfolio of prescription medicines addressing cardiovascular, respiratory, central nervous system, gastrointestinal, immunology, musculoskeletal, genetic, metabolic, and hematological disorders. In the consumer health segment, GC Biopharma offers over-the-counter products such as anti-inflammatory medicines, anti-allergy treatments, and other self-care options. The company’s research and development activities focus on advancing new therapies for cancer, tuberculosis, and Hunter syndrome, as well as additional unmet medical needs. GC Biopharma is headquartered Yongin, Gyeonggi-do, South Korea.

GC Biopharma Corp Key Recent Developments

  • Sep 11, 2026: GC Green Cross Receives IND Approval for Phase 2 COVID-19 mRNA Vaccine Trial
  • Sep 09, 2026: GC Green Cross Receives Korea Pharmaceutical and Bio Association Chair Award for 2026 Open Innovation Merit
  • Sep 09, 2026: GC Green Cross Receives Chair Award From Korea Pharmaceutical and Bio-Pharma Association
  • Sep 04, 2026: GC Green Cross Secures IND Approval for Phase 2/3 High-Immunogenicity Influenza Vaccine Trial

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • GC Biopharma Corp - Key Facts
  • GC Biopharma Corp - Key Employees
  • GC Biopharma Corp - Key Employee Biographies
  • GC Biopharma Corp - Major Products and Services
  • GC Biopharma Corp - History
  • GC Biopharma Corp - Company Statement
  • GC Biopharma Corp - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • GC Biopharma Corp - Business Description
  • Business Segment: Diagnosis and analysis of specimens
  • Overview
  • Performance
  • Business Segment: Manufacturing and sale of pharmaceuticals
  • Overview
  • Performance
  • Business Segment: Others
  • Overview
  • Performance
  • Geographical Segment: Domestic
  • Performance
  • Geographical Segment: Overseas
  • Performance
  • R&D Overview
  • GC Biopharma Corp - Corporate Strategy
  • GC Biopharma Corp - SWOT Analysis
  • SWOT Analysis - Overview
  • GC Biopharma Corp - Strengths
  • GC Biopharma Corp - Weaknesses
  • GC Biopharma Corp - Opportunities
  • GC Biopharma Corp - Threats
  • GC Biopharma Corp - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • GC Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • GC Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • GC Biopharma Corp, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Sep 11, 2026: GC Green Cross Receives IND Approval for Phase 2 COVID-19 mRNA Vaccine Trial
  • Sep 09, 2026: GC Green Cross Receives Korea Pharmaceutical and Bio Association Chair Award for 2026 Open Innovation Merit
  • Sep 09, 2026: GC Green Cross Receives Chair Award From Korea Pharmaceutical and Bio-Pharma Association
  • Sep 04, 2026: GC Green Cross Secures IND Approval for Phase 2/3 High-Immunogenicity Influenza Vaccine Trial
  • Aug 31, 2026: GC Green Cross Names Kim Yeon-koung as Model for Zenol Patch
  • Aug 13, 2026: GC Green Cross Shares COVID-19 mRNA Vaccine Progress at Korea Disease Control and Prevention Agency Event
  • Apr 06, 2026: GC Biopharma Improves IVIG Safety With Advanced Prothrombotic Impurity Detection
  • Apr 06, 2026: GC Biopharma Enhances IVIG Safety Profile with Advanced Prothrombotic Impurity Detection Technology
  • Mar 26, 2026: GC Biopharma Receives Marketing Authorization for Varicella Vaccine BARYCELA Inj. in Guatemala
  • Feb 20, 2026: GC Pharma Holds "GC ENDO Bridge Symposium" Relay Webinar for Medical Professionals
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact Us
  • Disclaimer
List of Tables
  • GC Biopharma Corp, Key Facts
  • GC Biopharma Corp, Key Employees
  • GC Biopharma Corp, Key Employee Biographies
  • GC Biopharma Corp, Major Products and Services
  • GC Biopharma Corp, History
  • GC Biopharma Corp, Other Locations
  • GC Biopharma Corp, Subsidiaries
  • GC Biopharma Corp, Key Competitors
  • GC Biopharma Corp, Ratios based on current share price
  • GC Biopharma Corp, Annual Ratios
  • GC Biopharma Corp, Interim Ratios
  • GC Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • GC Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • GC Biopharma Corp, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • GC Biopharma Corp, Performance Chart (2021 - 2025)
  • GC Biopharma Corp, Ratio Charts
  • GC Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • GC Biopharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Kolon Life Science Inc
  • Genexine Inc
  • AptaBio Therapeutics Inc
  • Hwail Pharma Co Ltd
  • Huons Global Co Ltd
  • Helixmith Co Ltd
  • Suheung Capsule Co Ltd
  • Jeil Pharmaceutical Co Ltd
  • Polaris AI Pharma Corp
  • TiumBio Co Ltd
  • Seoul Pharma Co Ltd
  • Sam Chun Dang Pharm Co Ltd
  • Yuhan Corp